Syndax Pharmaceuticals Quarterly Balance Sheet
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals financial position
As of Jun 30, 2026, Syndax Pharmaceuticals reported total assets of $703.7 million, up 18.0% from a year earlier against total liabilities of $688.6 million. Shareholders' equity stood at $15.1 million, or 2.1% of assets. The company held $336.5 million in cash and equivalents against $344.0 million of debt, a net debt position of $7.5 million.
The current ratio (current assets divided by current liabilities) was 6.77, meaning short-term assets cover obligations due within a year. Debt-to-equity was 22.78.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 336.48M | 130.89M | 134.93M | 116.81M | 108.64M | 153.99M | 154.08M | 133.02M | 105.40M | 114.61M | 295.39M | 94.55M |
| Short-Term Investments | 211.38M | 221.17M | 259.14M | 319.17M | 346.60M | 358.20M | 418.80M | 256.59M | 319.70M | 319.96M | 275.30M | 269.01M |
| Receivables | — | — | 38.00M | — | — | — | 7.60M | — | — | — | 0 | — |
| Inventory | 33.16M | 34.95M | 32.75M | 25.00M | 17.70M | 4.66M | 366.00K | — | — | — | 0 | — |
| Total Current Assets | 675.04M | 471.18M | 528.08M | 529.83M | 531.68M | 548.75M | 603.06M | 414.81M | 446.06M | 453.90M | 580.88M | 380.97M |
| Property, Plant & Equipment | 212.00K | 177.00K | 181.00K | 128.00K | 0 | 0 | 0 | 0 | 2.00K | 5.00K | 8.00K | 10.00K |
| Long-Term Investments | 27.22M | — | 0 | 20.15M | 62.63M | 89.94M | 119.52M | 10.03M | 29.52M | 87.42M | 29.83M | 15.71M |
| Total Assets | 703.65M | 472.67M | 529.71M | 551.79M | 596.15M | 640.71M | 724.82M | 425.81M | 476.95M | 543.03M | 612.88M | 399.22M |
| Accounts Payable | 4.87M | 10.84M | 16.58M | 13.83M | 17.35M | 10.05M | 11.63M | 4.90M | 11.57M | 8.81M | 9.96M | 6.05M |
| Short-Term Debt | 344.03M | 343.96M | 343.91M | 343.91M | 343.85M | 343.79M | 343.68M | — | — | — | 0 | — |
| Total Current Liabilities | 99.68M | 86.17M | 120.12M | 114.19M | 112.99M | 94.55M | 103.55M | 59.38M | 42.47M | 50.80M | 58.10M | 39.17M |
| Long-Term Debt | — | — | — | — | — | — | 331.56M | — | — | — | 0 | — |
| Total Liabilities | 688.55M | 431.05M | 465.08M | 436.36M | 438.73M | 425.65M | 436.69M | 59.38M | 42.61M | 51.14M | 58.68M | 40.04M |
| Shareholders' Equity | 15.10M | 41.62M | 64.63M | 115.43M | 157.42M | 215.06M | 288.12M | 366.43M | 434.34M | 491.89M | 554.20M | 359.19M |
| Retained Earnings | -1.60B | -1.55B | -1.51B | -1.44B | -1.38B | -1.31B | -1.22B | -1.13B | -1.04B | -974.80M | -902.40M | -829.93M |
| Total Debt | 344.03M | 343.96M | 343.91M | 343.91M | 343.85M | 343.79M | 675.25M | — | — | — | 0 | — |
| Net Cash (Debt) | 203.83M | 8.10M | 50.16M | 92.07M | 111.39M | 168.40M | -102.36M | 389.61M | 425.10M | 434.58M | 570.70M | 363.56M |
| Shares Outstanding | 89.15M | 88.54M | 87.41M | 86.91M | 86.06M | 86.05M | 85.69M | 85.57M | 85.03M | 84.98M | 84.83M | 69.64M |
This table shows 12 quarterly periods of Syndax Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SNDX's reporting calendar. What is a balance sheet?